{"id":"W4412708027","doi":"10.1016/j.esmoop.2025.105506","title":"Circulating tumor DNA mutational landscape and dynamics after progression on a CDK4/6 inhibitor in the PACE phase II trial for metastatic HR-positive/HER2-negative breast cancer","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Bristol-Myers Squibb; Samsung; Genentech; Natera; Seagen; Puma Biotechnology; Pfizer; Incyte; BeiGene; Mersana Therapeutics; Menarini Silicon Biosystems; Astex Pharmaceuticals; Eisai; Jazz Pharmaceuticals; McGill University; Daiichi Sankyo Europe; Gilead Sciences; Sanofi; Exelixis; GlaxoSmithKline; Amgen; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Fulvestrant; Palbociclib; Metastatic breast cancer; Oncology; Internal medicine; Cancer research; Cancer; Breast cancer; Medicine; Biology; Estrogen receptor","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001640869,0.0002429883,0.0004682982,0.0002148232,0.0001745106,0.0004902077,0.0002774794,0.000349636,0.002005365],"category_scores_gemma":[0.002286823,0.0001921082,0.0002336742,0.0002484711,0.0002566805,0.0004005469,0.000247018,0.0006981186,0.0002743082],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002581725,"about_ca_system_score_gemma":0.0003778154,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001538849,"about_ca_topic_score_gemma":0.0003098554,"domain_scores_codex":[0.9995146,0.0002013554,0.00002165794,0.0001252041,0.00008519072,0.00005200676],"domain_scores_gemma":[0.9990788,0.0002967912,0.0002935078,0.00007211455,0.00007903588,0.0001797266],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.2870932,0.003878232,0.531994,0.0003580365,0.00105438,0.0003870137,0.0004447708,0.004430588,0.0607812,0.0004680339,0.005902732,0.1032079],"study_design_scores_gemma":[0.03180736,0.0844839,0.8458138,0.0000475211,0.001085078,0.001402294,0.0001927704,0.007016576,0.01768496,0.001057557,0.009358469,0.00004984322],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9980618,0.0004849224,0.0001748477,0.00006310372,0.00001264688,0.00006275982,0.0005171529,0.00001568267,0.0006070897],"genre_scores_gemma":[0.9973438,0.0001428817,0.0003724024,0.0000917284,0.00004305226,0.0001185829,0.001327167,0.000008010522,0.000552403],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002005365,"threshold_uncertainty_score":0.00867784,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01736116853606104,"score_gpt":0.3840519532464865,"score_spread":0.3666907847104255,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}